Premium
A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project
Author(s) -
Smalley R. V.,
Carpenter J.,
Bartolucci A.,
Vogel C.,
Krauss S.
Publication year - 1977
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197708)40:2<625::aid-cncr2820400206>3.0.co;2-m
Subject(s) - medicine , fluorouracil , cyclophosphamide , vincristine , methotrexate , nausea , prednisone , vomiting , gastroenterology , cancer , chemotherapy , surgery
Abstract In an ongoing prospective randomized study, 113 evaluable patients have received either a three‐drug combination that included cyclophosphamide, Adriamycin and 5‐fluorouracil (CAF) or a five‐drug combination including cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine and prednisone (CMFVP) given intermittently 1 week out of 4. Responses (64%), median duration of response (32 weeks), and median duration of disease control (32 weeks) achieved with CAF were superior to those achieved with CMFVP (37%, 22 weeks, 17 weeks, respectively). Morbidity secondary to CAF was significant, with nausea and vomiting, malaise, total alopecia, and granulocytopenia being the main features. Cancer 40:625–632, 1977.